Update on the management of neuroendocrine hepatic metastases

Journal of Vascular and Interventional Radiology

Volumn 17, Issue 8, 2006, Pages 1235-1250

  Madoff, David C ^a   Gupta, Sanjay ^a   Ahrar, Kamran ^a   Murthy, Ravi ^a   Yao, James C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ALCOHOL; ALPHA INTERFERON; ANGIOPEPTIN; BEVACIZUMAB; DACARBAZINE; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; OCTREOTIDE; PENTETREOTIDE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; YTTRIUM 90;

ARTIFICIAL EMBOLISM; CATHETER ABLATION; CLINICAL TRIAL; CRYOSURGERY; GALLSTONE; GASTROINTESTINAL TUMOR; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIVER METASTASIS; LIVER TRANSPLANTATION; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL CARCINOMA; PRIORITY JOURNAL; RESPIRATORY TRACT TUMOR; REVIEW; SINUS BRADYCARDIA; STEATORRHEA; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CRYOSURGERY; ETHANOL; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASMS, UNKNOWN PRIMARY; NEUROENDOCRINE TUMORS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RADIOLOGY, INTERVENTIONAL; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33747451604     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000232177.57950.71     Document Type: Review

References (110)

1. Moertel CG. Karnofsky Memorial Lecture: an odyssey in the land of small tumors. J Clin Oncol 1987; 5:1503-1522.
2. Shebani KO, Souba WW, Finkelstein DM, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999; 229:815-823.
3. Norheim I, Oberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumors. Ann Surg 1987; 206:115-125.
4. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79:813-829.
5. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340:858-868.
6. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190:432-445.
7. Talamonti MS, Stuart K, Yao JC. Neuroendocrine tumors of the gastrointestinal tract: how aggressive should we be? In: Perry M, ed. American Society of Clinical Oncology 2004 Education Book. Alexandria: American Society of Clinical Oncology, 2004;206-215.
8. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22:4762-4771.
9. Venook AP. Embolization and chemoembolization therapy for neuroendocrine tumors. Curr Opin Oncol 1999; 11:38-41.
10. Schnirer II, Yao JC, Ajani JA. Carcinoid: a comprehensive review. Acta Oncol 2003; 42:672-692.
11. Capella C, Heitz PU, Hofler H, et al. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 1994; 55(suppl 3):11-23.
12. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54(suppl 4):iv1-iv16.
13. Rappeport ED, Hansen CP, Kjaer A, et al. Multidetector computed tomography and neuroendocrine pancreaticoduodenal tumors. Acta Radiol 2006; 47:248-256.
14. Horton KM, Hruban RH, Yeo C, et al. Multi-detector row CT of pancreatic islet cell tumors. Radiographics 2006; 26:453-464.
15. Fidler JL, Fletcher JG, Reading CC, et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. AJR Am J Roentgenol 2003; 181:775-780.
16. King AD, Ko GT, Yeung VT, et al. Dual phase spiral CT in the detection of small insulinomas of the pancreas. Br J Radiol 1998; 71:20-23.
17. Ichikawa T, Peterson MS, Federle MP, et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 2000; 216:163-171.
18. Van Hoe L, Gryspeerdt S, Marchal G, et al. Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images. AJR Am J Roentgenol 1995; 165:1437-1439.
19. Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005; 23:70-78.
20. Krenning EP, Kooij PPM, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. Ann N Y Acad Sci 1994; 733:496-506.
21. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38:430-438.
22. Saltz L, Trochanowski B, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993; 72:244-248.
23. Cascinu S, Del Ferro E, Ligi M, et al. Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest 2001; 19:8-12.
24. Pollak MN, Polychronakos C, Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 1989; 9:889-891.
25. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17:600-606.
26. Janson EM, Ahlstrom H, Andersson T, et al. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 1992; 10:1647-1650.
27. Janson ET, Oberg K. Long-term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993; 32:225-229.
28. Frank M, Klose KJ, Wied M, et al. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999; 94:1381-1387.
29. Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005; 23:4897-4904.
30. Kolby L, Persson G, Franzen S, et al. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003; 90:687-693.
31. Yao JC, Ng C, Hoff PM, et al. Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab [abstract]. J Clin Oncol 2005; 23(16 suppl):309s.
32. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97:934-59.
33. Chernicoff D, Bukowski RM, Groppe Jr, CW et al. Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozotocin. Cancer Treat Rep 1979; 63:795-796.
34. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980; 303:1189-1194.
35. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma [comment]. N Engl J Med 1992; 326:519-523.
36. Eriksson B, Oberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993; 32:203-208.
37. Eriksson B, Skogseid B, Lundqvist G, et al. Medical treatment and longterm survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990; 65:1883-1890.
38. McCollum AD, Kulke MH, Ryan DP, et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004; 27:485-488.
39. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999; 86:944-948.
40. von Schrenck T, Howard JM, Doppman JL, et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 1988; 94:1326-1334.
41. Rivera E, Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 1998; 21:36-38.
42. Ramanathan RK, Cnaan A, Hahn RG, et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001; 12:1139-1143.
43. Fine R, Fogelman D, Schreibman S. Effective treatment of neuroendocrine tumors with temozolomide and capecitabine [abstract]. J Clin Oncol 2005; 23(16 suppl):361s.
44. Kulke MH, Lenz HJ, Meropol NJ, et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs) [abstract]. J Clin Oncol 2005; 23(16 suppl):310s.
45. Fraker DL, Norton JA. Localization and resection of insulinomas and gastrinomas. JAMA 1988; 259:3601-3605.
46. Yao JC, Vauthey JN. Primary and metastatic hepatic carcinoid: is there an algorithm? Ann Surg Oncol 2003; 10:1133-1135.
47. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001; 130:677-682.
48. McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108:1091-1096.
49. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169:36-42.
50. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197:29-37.
51. Chen H, Hardacre JM, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998; 187:88-92.
52. Soreide O, Berstad T, Bakka A, et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 1992; 111:48-54.
53. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13:572-581.
54. Sarmiento JM, Que FG, Grant CS, et al. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 2002; 132:976-982.
55. Norton JA, Kivlen M, Li M, et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003; 138:859-866.
56. Madoff DC, Abdalla EK, Gupta S, et al. Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils. J Vasc Interv Radiol 2005; 16:215-225.
57. Madoff DC, Abdalla EK, Vauthey JN. Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol 2005; 16:779-790.
58. Le Treut YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997; 225:355-364.
59. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 1998; 66:1307-1312.
60. Rosenau J, Bahr MJ, von Wasielewski R, et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 2002; 73:386-394.
61. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994; 120:302-309.
62. Hajarizadeh H, Ivancev K, Mueller CR, et al. Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. Am J Surg 1992; 163:479-483.
63. Hanssen LE, Schrumpf E, Kolbenstvedt AN, et al. Recombinant alpha-2 interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumours: a preliminary report. Acta Oncol 1989; 28:439-443.
64. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors: a prospective phase II study in 24 patients. Cancer 1993; 71:2624-2630.
65. Therasse E, Breittmayer F, Roche A, et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 1993; 189:541-547.
66. Wangberg B, Westberg G, Tylen U, et al. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 1996; 20:892-899.
67. Kim YH, Ajani JA, Carrasco CH, et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 1999; 17:474-478.
68. Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83:2293-2301.
69. Dominguez S, Denys A, Madeira I, et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol 2000; 12:151-157.
70. Carrasco CH, Chuang VP, Wallace S. Apudomas metastatic to the liver: treatment by hepatic artery embolization. Radiology 1983; 149:79-83.
71. Roche A, Girish BV, de Baere T, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003; 13:136-140.
72. Loewe C, Schindl M, Cejna M, et al. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and Lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol 2003; 180:1379-1384.
73. Drougas JG, Anthony LB, Blair TK, et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 1998; 175:408-412.
74. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003; 9:261-267.
75. Mavligit GM, Pollock RE, Evans HL, et al. Durable hepatic tumor regression after arterial chemoembolization-infusion in patients with islet cell carcinoma of the pancreas metastatic to the liver. Cancer 1993; 72:375-380.
76. Ajani JA, Carrasco CH, Charnsangavej C, et al. Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med 1988; 108:340-344.
77. Stokes KR, Stuart K, Clouse ME. Hepatic arterial chemoembolization for metastatic endocrine tumors. J Vasc Interv Radiol 1993; 4:341-345.
78. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104:590-602.
79. Kress O, Wagner HJ, Wied M, et al. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors: a retrospective single-center analysis. Digestion 2003; 68:94-101.
80. Nave H, Mossinger E, Feist H, et al. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 2001; 129:170-175.
81. Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 2005; 25(suppl):S41-S55.
82. Salem R, Atassi B, Gordon SC, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16:1627-1639.
83. Lewandowski RJ, Goin JE, Wong C, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F] fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005; 16:1641-1651.
84. Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 2005; 16:937-945.
85. Mantravadi R, Spigos D, Tan W, et al. Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology 1982; 142:783-786.
86. Blanchard R, Morrow I, Sutherland J. Treatment of liver tumors with yttrium-90 microspheres alone. Can Assoc Radiol J 1989; 40:206-210.
87. Herba M, Illescas F, Thirlwell M, et al. Hepatic malignancies: improved treatment with intraarterial Y-90. Radiology 1988; 169:311-314.
88. Andrews J, Walker S, Ackermann R, et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994; 35:1637-1644.
89. Coldwell D. Use of Yttrium-90 SIR-Spheres to treat unresectable metastatic neuroendocrine tumors to the liver. Presented at the 7th World Congress on Gastrointestinal Cancer, June 15-18, 2005; Barcelona, Spain. Abstract O-002.
90. Murthy R, Gupta S, Madoff DC, et al. Feasibility of hepatic arterial therapy with Yttrium-90 microspheres, SIR-Spheres®, in metastatic neuroendocrine neoplasia with hepatic dominant progression after failure of multiple systemic and hepatic artery therapies [abstract]. Radiology 2005; 237(suppl):410
91. Breeman WA, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001; 28:1421-1429.
92. McStay MK, Maudgil D, Williams M, et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 2005; 237:718-726.
93. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002; 26:985-990.
94. Gillams A, Cassoni A, Conway G, et al. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005; 30:435-441.
95. Henn AR, Levine EA, McNulty W, et al. Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. AJR Am J Roentgenol 2003; 181:1005-1010.
96. Wettstein M, Vogt C, Cohnen M, et al. Serotonin release during percutaneous radiofrequency ablation in a patient with symptomatic liver metastases of a neuroendocrine tumor. Hepatogastroenterology 2004; 51:830-832.
97. Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000; 214:761-768.
98. Yamakado K, Nakatsuka A, Ohmori S, et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol 2002; 13:1225-1232.
99. Shafir M, Shapiro R, Sung M. et al. Cryoablation of unresectable malignant liver tumors. Am J Surg 1996; 171:27-31.
100. Cozzi PJ, Englund R, Morris DL. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer 1995; 76:501-509.
101. Sheen AJ, Poston GJ, Sherlock DJ. Cryotherapeutic ablation of liver tumours. Br J Surg 2002; 89:1396-1401.
102. Duperier T, Ali A, Pereira S et al. Laparoscopic cryoablation of a metastatic carcinoid tumor. J Laparoendosc Adv Surg Tech A 2001; 11:105-109.
103. Shapiro RS, Shafir M, Sung M, et al. Cryotherapy of metastatic carcinoid tumors. Abdom Imaging 1998; 23:314-317.
104. Tait IS, Yong SM, Cuschieri SA. Laparoscopic in situ ablation of liver cancer with cryotherapy and radiofrequency ablation, Br J Surg 2002; 89:1613-1619.
105. Livraghi T, Vettori C, Lazzaroni S. Liver metastases: results of percutaneous ethanol injection in 14 patients. Radiology 1991; 179:709-712.
106. Atwell TD, Charboneau JW, Que FG, et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol 2005; 28:409-421.
107. Livraghi T, Goldberg SN, Lazzaroni S. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210:655-661.
108. Lencioni R, Allgaier HP, Cioi D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228:235-40.
109. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors, Version 1. Jenkintown, PA: National Comprehensive Cancer Network, 2006.
110. Hobday T, Mahoney M, Erlichman C, et al. Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study [abstract]. J Clin Oncol 2005; 23(16 suppl):328s.